Impaired health‐related quality of life in Addison's disease – impact of replacement therapy, comorbidities and socio‐economic factors
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Patients with Addison's disease (AD) on conventional replacement therapy have impaired health‐related quality of life (HRQ oL). It is possible that lower hydrocortisone (HC) doses recommended by current guidelines could restore HRQ oL. We compared HRQ oL in AD patients treated according to current HC recommendations to that of the age‐ and gender‐standardized general population. Subjects, design and measurement: We assessed HRQ oL in a cross‐sectional setting with the 15D instrument in a Finnish AD cohort (n = 107) and compared the results with those of a large sample of general population (n = 5671). We examined possible predictors of HRQ oL in AD. Within the patient group, HRQ oL was also assessed by SF‐36. Results: Mean HC dose was 22 mg/d, corresponding to 12 ± 4 mg/m2. HRQ oL was impaired in AD compared with the general population (15D score; 0·853 vs 0·918, P < 0·001). Within single 15D dimensions, discomfort and symptoms, vitality and sexual activity were most affected. Stepwise regression analysis demonstrated that Patient's Association membership (P = 0·02), female gender (P < 0·01), presence of other autoimmune or inflammatory comorbidity (P < 0·02), lower education (P < 0·02) and longer disease duration (P < 0·05) independently predicted impaired HRQ oL, whereas replacement regimens, autoimmune‐related comorbidities, total number of comorbidities or level of healthcare follow‐up did not. In AD, HRQ oL was impaired also as assessed by SF‐36. Conclusions: HRQ oL is significantly impaired in AD compared with the general population despite use of recommended HC doses. Patient's Association membership was the most significant predictor of impaired HRQ oL. This finding should be explored in more detail in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 1×
“Without life-long replacement therapy, Addison’s disease (AD) has devastating consequences, but even when treated AD has been associated with increased mortality (1).”
BackgroundHusebye, E. S., Allolio, B., Arlt, W., Badenhoop, K., Bensing, S., Betterle, C., Falorni, A., Gan, E. H., Hulting, A. ‐., Kasperlik‐Zaluska, A., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12162 · Cited by 403 · cited 3×
“During the last years, smaller HC replacement doses have been recommended (11,14) and a recent consensus statement on AD suggests 15-25 mg per day (15).”
BackgroundHahner, S., Loeffler, M., Fassnacht, M., Weismann, D., Koschker, A.-C., Quinkler, M., Decker, O., Arlt, W., & Allolio, B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0685 · Cited by 282
Erichsen, M. M., Løvås, K., Fougner, K. J., Svartberg, J., Hauge, E. R., Bollerslev, J., Berg, J. P., Mella, B., & Husebye, E. S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0550 · Cited by 240
Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial
Gurnell, E. M., Hunt, P. J., Curran, S. E., Conway, C. L., Pullenayegum, E. M., Huppert, F. A., Compston, J. E., Herbert, J., & Chatterjee, V. K. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1134 · Cited by 189 · cited 5×
“In addition, the well-being of AD patients may be affected by loss of adrenal dehydroepiandrosterone (DHEA) secretion (9,11).”
BackgroundResultInfluentialThe approach to the adult with newly diagnosed adrenal insufficiency
Arlt, W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0032 · Cited by 165 · cited 5×
“In addition, the well-being of AD patients may be affected by loss of adrenal dehydroepiandrosterone (DHEA) secretion (9,11).”
BackgroundInfluentialLøvås, K., Gebre-Medhin, G., Trovik, T. S., Fougner, K. J., Uhlving, S., Nedrebø, B. G., Myking, O. L., Kämpe, O., & Husebye, E. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020769 · Cited by 144
Adrenal insufficiency: etiology, diagnosis and treatment
Neary, N., & Nieman, L. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328338f608 · Cited by 140 · cited 2×
“During the last years, smaller HC replacement doses have been recommended (11,14) and a recent consensus statement on AD suggests 15-25 mg per day (15).”
BackgroundForss, M., Batcheller, G., Skrtic, S., & Johannsson, G. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-8 · Cited by 109 · cited 2×
“The mean HC dosage per body surface area was 12 mg/m2 ± 4 (7-21).”
BackgroundØksnes, M., Bensing, S., Hulting, A.-L., Kämpe, O., Hackemann, A., Meyer, G., Badenhoop, K., Betterle, C., Parolo, A., Giordano, R., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1901 · Cited by 99 · cited 3×
“Of note, a recently published disease-specific HRQoL questionnaire for AD is not yet available in Finnish and could therefore not be used (25,35).”
BackgroundThe risk of affective disorders in patients with adrenocortical insufficiency
Thomsen, A. F., Kvist, T. K., Andersen, P. K., & Kessing, L. V. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.01.003 · Cited by 79
Ekman, B., Bachrach‐Lindström, M., Lindström, T., Wahlberg, J., Blomgren, J., & Arnqvist, H. J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04352.x · Cited by 54
Libè, R., Barbetta, L., Dall’Asta, C., Salvaggio, F., Gala, C., Beck-Peccoz, P., & Ambrosi, B. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03347515 · Cited by 51 · cited 1×
“As demonstrated previously (4, 29, 30), DHEA supplementation was not associated with improved HRQoL in female AD patients.”
BackgroundPeters, C. J., Hill, N., Dattani, M. T., Charmandari, E., Matthews, D. R., & Hindmarsh, P. C. (2013) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04502.x · Cited by 34 · cited 3×
“On the other hand, replacement therapy with any current glucocorticoid regimen does not mimic the circadian physiological cortisol profile and patients on HC replacement therapy spend the early morning hours in a glucocorticoid deficient state (13).”
BackgroundAlonso, N., Granada, M. L., Lucas, A., Salinas, I., Reverter, J., Oriol, A., & Sanmartí, A. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345290 · Cited by 30 · cited 1×
“Several studies addressing the subjective health status of patients with AD demonstrated a negative impact on health-related quality of life (HRQoL) (2-7).”
Background
Cited by
Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy
Alam, J., Jantan, I., & Bukhari, S. N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.055 · Cited by 280
Hahner, S., Ross, R. J., Arlt, W., Bancos, I., Burger-Stritt, S., Torpy, D. J., Husebye, E. S., & Quinkler, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00252-7 · Cited by 223
Mazziotti, G., Formenti, A. M., Frara, S., Roca, E., Mortini, P., Berruti, A., & Giustina, A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0154 · Cited by 96
Gagliardi, L., Nenke, M. A., Thynne, T. R. J., von der Borch, J., Rankin, W. A., Henley, D. E., Sorbello, J., Inder, W. J., & Torpy, D. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2433 · Cited by 85
Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation
Burger-Stritt, S., Eff, A., Quinkler, M., Kienitz, T., Stamm, B., Willenberg, H. S., Meyer, G., Klein, J., Reisch, N., Droste, M., et al. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0181 · Cited by 36
Metadata
- Authors
- Kluger, N., Matikainen, N., Sintonen, H., Ranki, A., Roine, R. P., & Schalin‐Jäntti, C.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2014-06-12
- Volume
- 81
- Issue
- 4
- Pages
- 511-518
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2092505805
- Cited by
- 41
- References
- 15
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.